Kenneth Saag
Rheumatology · Birmingham, ALNPI 1023033917
Payments from drug & device makers
Across 226 payments — averaging $36,380 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$8M
- Radius Health, Inc.$99K
- Swedish Orphan Biovitrum AB$25K
- Neurocrine Biosciences, Inc.$15K
- Daiichi Sankyo Company LTD$13K
- CSL Behring$6K
- plus $33K from 17 others
Across 17 payments — averaging $550.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$3K
- Sanofi-aventis U.S. LLC$3K
- Radius Health, Inc.$2K
- Takeda Pharmaceuticals U.S.A., Inc.$952
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 84 | $8,030,030 |
| Radius Health, Inc. | 78 | $98,517 |
| Swedish Orphan Biovitrum AB | 15 | $25,402 |
| Neurocrine Biosciences, Inc. | 8 | $15,006 |
| Daiichi Sankyo Company LTD | 4 | $13,312 |
| CSL Behring | 4 | $6,200 |
| AbbVie | 8 | $5,947 |
| Gilead | 3 | $4,560 |
| Chugai Pharmaceutical Co., Ltd. | 3 | $4,313 |
| Sanofi | 1 | $4,214 |
| Sobi, Inc | 2 | $3,044 |
| Kyowa Kirin, Inc. | 3 | $2,497 |
| Regeneron | 1 | $1,740 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $1,556 |
| Lilly USA, LLC | 1 | $1,307 |
| Kyowa Kirin Co., Ltd | 1 | $1,110 |
| Mallinckrodt Hospital Products Inc. | 1 | $1,000 |
| Eli Lilly | 1 | $800 |
| GRT US Holding, Inc. | 1 | $758 |
| Aurinia Pharma U.S., Inc. | 1 | $125 |
| AstraZeneca | 1 | $123 |
| GSK | 1 | $118 |
| UCB SA | 1 | $108 |
How this compares
$8,221,787 in reported general payments places this provider in the 95th percentile of 90 rheumatology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Birmingham
- Jeffrey CurtisBirmingham$17.6M
- Harry SchroederBirmingham$938K
- Jose Rubio MosqueraBirmingham$823K
- David McLainBirmingham$588K
- Maria DanilaBirmingham$196K
- James AndrewsBirmingham$192K
- Angelo Gaffo LlontopBirmingham$182K
- Matthew MullenBirmingham$38K
- Greg EudyBirmingham$33K
- John MorganBirmingham$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.